SecBot SecBot
8-K ·Filed Nov 4, 2026

INVA

Innoviva, Inc.
BEARISH
Impact 5/10
Horizonimmediate Processed12d 7h ago SEC0001193125-26-447366
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The revenue miss and GAAP net loss driven by investment mark-to-market are the headline negatives, but operating income grew 22% and IST product sales accelerated 45% YoY. Watch for Q4 revenue trajectory and whether NUZOLVENCE adoption can offset continued royalty erosion from GSK.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

INVA drug pipeline →

GIAPREZA

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available (FDA approved December 2017).
Next catalyst
None dated

What to watchGIAPREZA has no upcoming FDA decision or pivotal readout; the next catalyst for Innoviva is the Q4 2026 earnings report (likely February 2027), where GIAPREZA's continued sales growth trajectory will be the key metric to watch. The drug's $23.1M quarterly run rate is on pace to help Innoviva hit its at-least-$150M full-year IST product sales guidance.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$19.24
T+0 close · Nov 4, 2026 · via day close
Latest settled
−1.40%
T+5 · $18.97 · next T+20 in 17d
Vs SPY
−4.69%
α at T+5
Latest observation
+0.74%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $19.24entry
  2. T+1 · 11d ago −0.73%α −1.04% · $19.10
  3. T+5 · 5d ago −1.40%α −4.69% · $18.97
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Innoviva Q3 2026 total revenue of $106.1M declined 1.6% YoY, missing the $115.3M consensus, as lower royalty revenue and ex-U.S. timing offset 45% growth in U.S. IST net product sales to $43.3M. GAAP net loss of $73.9M ($1.03 basic loss) was driven by a $139.5M unfavorable fair-value change in equity investments, primarily Armata Pharmaceuticals. The company maintained its 2026 U.S. IST sales guidance of at least $150M and repurchased 1.2M shares for $26.3M in Q3.

Key Financial Metrics

EPS
−$1.03
Revenue
$106.1M
est $115.3M · -8.0% · -1.6% YoY
Gross Margin
79.5%

Key Facts

  • Total revenue $106.1M, down 1.6% YoY from $107.8M, missing $115.3M consensus
  • GAAP net loss of $73.9M ($1.03 basic loss) vs net income of $89.9M ($1.30 basic) in Q3 2025
  • U.S. IST net product sales $43.3M, up 45% YoY from $29.9M
  • Gross royalty revenue from GSK stable at $58.1M vs $63.4M in Q3 2025
  • Income from operations $42.2M, up 21.9% YoY from $34.6M
  • Net unfavorable fair-value changes in equity/long-term investments totaled $139.5M
  • Cash and cash equivalents $581.4M at Sept 30, 2026
  • Repurchased 1,226,948 shares for $26.3M in Q3; $82.7M total under $125M buyback program
  • NUZOLVENCE now commercially available in the U.S.
  • Maintained 2026 guidance of at least $150M in U.S. net product sales

Financial Impact

Revenue miss of ~$9.2M vs consensus; GAAP net loss of $73.9M vs prior-year net income of $89.9M; operating income grew 21.9% to $42.2M

revenuenet incomeEPSfair value of investments

Segment Breakdown

SegmentRevenueGrowth
Royalty revenue, net$54.7M-8.8%
Net product sales$49.4M+4.5%
License and other revenue$2.0M+231.0%

Risk Factors

  • Total revenue declined YoY and missed consensus, driven by lower GSK royalty revenue and ex-U.S. timing
  • GAAP net loss of $73.9M from $139.5M unfavorable fair-value changes in equity investments, primarily Armata Pharmaceuticals
  • Royalty revenue from GSK declining: gross royalties $58.1M vs $63.4M in Q3 2025
  • Selling, general and administrative expenses increased 35.6% YoY to $37.0M

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-447366
Document: d177079d8k.htm0001193125-26-447366
Document: 0001193125-26-447366-index-headers.html0001193125-26-447366
Document: 0001193125-26-447366-index.html0001193125-26-447366
Document: 0001193125-26-447366.txt0001193125-26-447366
8-K Data (Synthetic)0001193125-26-447366

Track record

5 reports on INVA

Performance horizon
Filters
  1. Nov 4, 202612d ago 8-K Bearish 5/10 Viewing Entry $19.24 to $18.97 Now $18.49 +3.90% ▲ +1.40% +4.69% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $21.12 to $21.26 Now $18.49 −12.45% ▲ +0.66% +1.38% vs SPY
  3. May 18, 202626w ago 8-K Neutral 3/10 Entry $21.73 to $22.13 Now $18.49 −14.91% ▲ +1.84% −0.46% vs SPY
  4. May 6, 202627w ago 8-K Mixed 5/10 Entry $22.80 to $23.14 Now $18.49 −18.90% ▲ +1.49% −0.01% vs SPY
  5. Mar 27, 202633w ago 10-K/A Neutral 3/10 Entry $22.91 to $23.28 Now $18.49 −19.29% ▲ +1.61% −2.69% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 9h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026